Role in PharmNovo: Chairman of the board.
Born: 1950.
Education: Juris Dr degree 1976 from University of Lund.
Other current appointments: Senior Advisor to HealthCap.
Work experience: AstraZeneca 32 years; Lagerlöfs Law Firm (today Linklaters) 1½ years. Associate at the law firm Linklaters (Lagerlöf at that time) in Stockholm for almost two years before joining Astra AB as Legal Counsel in 1980. Göran was General Counsel in 1984–1999 and Company Secretary of Astra AB 1988–1999. When Astra Zeneca Ltd was formed in 1999 Göran served as General Counsel Pharmaceuticals through 2008 and finished his career with the company as Deputy General Counsel IP Litigation until retirement early 2012. Göran was a Non-Executive Director of Astra Merck, Inc in the US 1994–1998.
Holdings: 40 000 shares.
Member of:
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read moreThe US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read moreOlof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more